Our Team
Bedford Bridge was founded by David and Eric Berry, who bring preeminent track records investing and operating in tech and biotech companies. We are a tight-knit, collaborative team that values integrity, innovation, and excellence in all that we do. We believe that by working together and leveraging our collective skills and knowledge, we can achieve great things for our portfolio companies and our investors.
David has co-founded over 30 companies across life sciences and sustainability as a General Partner at Flagship Pioneering. This includes at least 7 that were valued at over $1B each.
David has been broadly recognized as a world-leading innovator: elected as a Young Global Leader by the World Economic Forum, named as Innovator of the Year by MIT Technology Review from amongst its annual TR35 list, and selected as one of 12 Innovators Reshaping Reality by the U.S. State Department, alongside pioneers such as Tim Berners-Lee. He holds over 200 patents and patent applications.
David received his M.D. from Harvard Medical School and his Ph.D. from MIT in biological engineering, completing the fastest dual degree in the modern history of the program, during which he was awarded the Lemelson-MIT Prize award for the most inventive and innovative student at MIT.
Eric was the founder and CEO of TripleLift. He led the company from inception, raising only $16M in outside capital before selling a majority of the business to Vista Equity Partners for over $1.4B, one of the largest cash-on-cash returns in the history of New York tech. TripleLift was consistently a highly profitable "rule of" 70+ company, growing to well over $200M in revenue, operating across a dozen countries, while also executing 9-digit cross-border M&A.
Eric has been recognized as a highly successful entrepreneur, including as an EY Entrepreneur of the Year, along with several 40 under 40 awards. TripleLift was recognized by Inc. 5000 and Deloitte Fast 500 as being among the fastest growing companies in America for six consecutive years, while also regularly winning "Best Places to Work" awards from numerous publications.
Eric received his bachelors and masters degrees from MIT in computer science and electrical engineering and his J.D. from NYU School of Law.
Jeffrey was previously at Novo Holdings, where, he partnered with innovative life sciences platform and healthcare technology companies including Exscientia (NASDAQ: RXRX; led from first institutional financing to a $510m IPO, the largest of all-time by a European biotech, in 1.5 years), Tempus (NASDAQ: TEM; a $5.4b publicly traded company in January 2025), and Verana Health (leading real-world data provider backed by GV (formerly Google Ventures) and Johnson & Johnson).
Prior to Novo Holdings, Jeffrey was a Partner at Andreessen Horowitz (a16z) which he joined during the launch of their inaugural Bio Fund. There, he invested in pioneering biotech and healthcare technology companies including Accolade (NASDAQ: ACCD), AKASA Health, Asimov, Bayesian Health, BioAge Labs (NASDAQ: BIOA), CAMP4 Therapeutics (NASDAQ: CAMP), Ciitizen (acquired by Invitae), Devoted Health, Elegen, Erasca (NASDAQ: ERAS), Freenome, Genesis Therapeutics, Incredible Health, Insitro, Jungla (acquired by Invitae), Octant Bio, Omada Health, The One Health Company, and Patient Ping (acquired by Appriss Health).
Jeffrey received his MD from Yale School of Medicine, his MBA from Harvard Business School, and his AB in Molecular and Cellular Biology from Harvard.
Tristan was most recently the chief operating officer for Roivant Health, the platform within Roivant Sciences to build and scale new health technology companies. Tristan also served as an Expert-in-Residence (XIR) for Digitalis Commons, the non-profit sister organization to Digitalis Ventures. As an XIR he works to advise innovators working on early-stage health technologies and currently supports ARPA-H in translating scientific and technological breakthroughs into real-world products and services.
Previously, Tristan was a Partner in the New York office of Boston Consulting Group (BCG). As a physician and leader within BCG’s healthcare practice, he was an expert in growth strategy, innovation, and due diligence, serving clients ranging from Series A to Fortune 500 companies, as well as global health institutions, and principal investors.
Tristan received his MD from the Columbia University College of Physicians & Surgeons and his MBA from Columbia Business School, and his BS from the University of Notre Dame.
Ben was most recently at Taboola ($TBLA), where he led the Corporate Development team, identifying, conducting due diligence, and leading the negotiation process for international M&A transactions. A notable achievement includes leading the $800 million acquisition of Connexity, a transformative milestone for the company.
Ben has been an active angel investor. He has made over 30 early-stage investments across a number of sectors, including health and technology. He also has formal advisor agreements with many of these companies, who regularly seek out his guidance on growth and strategic direction. Notable investments include Mercury, Ezra, Reality Defender, SparkPlug, Apprenete, and Taiv. Ben is deeply connected with founders across the US and APAC regions, through both his professional corporate development experience and his extensive personal angel investing.
Ben graduated from Hamilton College, receiving the Earl H. Wright Prize for outstanding contributions to public discourse and advocacy.
Alex was most recently at OpenView Venture Partners, an expansion stage software investment firm, where he led all firm operations. At OpenView, he oversaw a wide range of functions including finance, talent management, investor relations, and operational strategy. His work was instrumental in scaling the firm's assets under management from $0.4 to $2+ billion and supporting the growth of numerous portfolio companies.
Prior to OpenView, Alex held roles at General Electric and Cimpress (fka Vistaprint), where he led various corporate finance functions.
Alex earned his BS from Bentley University and his MBA from Boston College.
Oanh was previously at Satellite Bio where she was an Executive Assistant to the CEO. Previously she was an Executive Assistant at Atlas Venture. She has also been an EA/Office Manager at Quartet Medicine, and an EA/HR Generalist at FORUM Pharmaceuticals.
Oanh earned her degree from Roger Williams University.